[Clinical experiences with femovan (Gynera)].
The low dose oral contraceptive Femovan/Gynera which contains 0.03 mg Ethinylestradiol and 0.075 mg Gestoden was examined in several clinical trials. Those trials proved its contraceptive effectiveness, its controlling influence on the menstrual cycle and a low incidence of unwanted side-effects. The data reported are based on the experience of more than 100,000 women representing nearly 600,000 treatment cycles. The results of all the different investigations compiled here underline a high contraceptive effectiveness and excellent control of the cycle when using the respective preparation. The rate of unwanted side-effects was low.
Brill
K
K
Pharma Deutschland Medizin, Schering Aktiengesellschaft, Berlin.
Düsterberg
B
B
Albring
M
M
D000293:Adolescent; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage / Q000009:adverse effects; D004997:Ethinyl Estradiol / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D008597:Menstrual Cycle / Q000187:drug effects; D009652:Norpregnenes / Q000008:administration & dosage* / Q000009:adverse effects; D013923:Thromboembolism / Q000139:chemically induced
D003277:Contraceptives, Oral, Combined; D009652:Norpregnenes; C055368:Femovan; D004997:Ethinyl Estradiol
Klinische Erfahrungen mit Femovan (Gynera).